News
-
8 June 2016
Immunocore’s ImmTAV shown to redirect the immune system to kill HIV-infected cells from patients treated with antiretroviral therapy -
6 June 2016
Immunocore Presents Positive IMCgp100 Phase I Data at the 2016 ASCO Annual Meeting -
30 March 2016
Immunocore’s IMCgp100 Starts Phase I Trial for the Treatment of Uveal Melanoma -
25 January 2016
Immunocore’s IMCgp100 Granted Orphan Drug Designation by US FDA for the Treatment of Uveal Melanoma -
20 January 2016
Immunocore Starts Clinical Trial with IMCgp100 in Combination with MedImmune Immunotherapies Durvalumab and Tremelimumab -
6 January 2016
Immunocore and GlaxoSmithKline Select First ImmTAC Clinical Candidate in Discovery Collaboration -
17 December 2015
Immunocore expands its senior management team and opens US Office -
3 December 2015
Immunocore wins Biotech of the Year at the SCRIP Awards 2015 -
9 September 2015
Immunocore’s IMCgp100 Accepted for Adaptive Pathway Pilot Programme -
7 September 2015
Immunocore Ranked No 1 South East Company in the Annual Sunday Times Hiscox Tech Track 100